ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1199

Validation of New Medication User Definitions in Single-Specialty EHR Data

Jeffrey Curtis1, Yujie Su2, Michael george3, Cassie Clinton2, Patrick Stewart4, Tim Buekelman5 and Fenglong Xie2, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3UPENN, Philadelphia, PA, 4Bendcare, Boca Raton, FL, 5FASTER, Hoover, AL

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Epidemiology, Pharmacoepidemiology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent a new medication start. The optimal implementation of new user designs in single-specialty EHR data is unknown.

Methods: We identified patients with new prescriptions for biologics or janus kinase inhibitors (JAKi) for RA or spondyloarthritis ordered by rheumatologists in the Illumination Health Real-World Evidence Platform (EHR data) linked to either fee-for-service Medicare or commercial health plan data (claims data). The first prescription observed in the EHR data for each medication anchored the index date. Drugs reported by the patient as part of medication reconciliation (one of the most adopted quality measures, MIPS #130) that preceded the first observed prescription in the EHR data were excluded. We tested 6 new user definitions that required a rheumatologist office visit, any prescription in the EHR data, or both, occurring in the EHR ≥ 12, or ≥ 24 months prior to index. We evaluated the positive predictive values (PPV) of the EHR new user definitions using an absence of previous prescription fills in claims data as the gold standard for determining whether prescriptions were truly new medication starts, using a 12-month baseline period and also an “all-available” lookback period prior to index (minimum of 12 months). For reference purposes, we also evaluated the amount of misclassification occurring if patient reported medications were not excluded.

Results: There were 7,478 medication initiations in patients linked to Medicare (mean[SD] patient age 69.6[10.4] years, 78.7% women) and 1,981 in patients linked to commercial claims (mean[SD] patient age 64.9[12.6] years, 78.6% women). Most patients in the cohort (81% Medicare, 75% Commercial) had RA. In Medicare and commercial health plan data, the mean(SD) years of prior claims data was 5.8(3.7) (Medicare) and 4.8(3.2) (commercial), and patients had previously filled a mean(SD) of 0.9(1.1) and 0.9(1.0) biologics or tsDMARDs, respectively. The PPVs of the 6 new user definitions ranged from 85-98% vs a fixed 12m claims-based gold standard, and 86-93% vs an “all-available data” claims-based gold standard in Medicare-linked patients (Table). PPVs ranged from 95-97% (vs fixed 12m claims-based gold standard) and 92-95% (vs all-available claims-based gold standard) in commercially insured patients. Compared to an EHR new user definition that only required a rheumatologist visit ≥12 months before new medication use, requiring both visits and medications, or using 24-month EHR baseline, increased PPVs by only 1-3% in both datasets with appreciable loss in sample size.

Conclusion: A new user definition for EHR data that requires ≥1 rheumatologist visit at least 12 months before first drug mention is a valid approach to identify new medication users. Although less accurate, excluding medications based only on patient-reported medication information collected during medication reconciliation also showed good performance with increased sample size.

Supporting image 1


Disclosures: J. Curtis, Amgen, Bristol-Myers Squibb (BMS), CorEvitas, IlluminationHealth, Janssen, Lilly, Myriad, Novartis, Pfizer, Sanofi, UCB, Aqtual, Bendcare, FASTER, GlaxoSmithKlein (GSK), Labcorp, Scipher, Setpoint, United Rheumatology, AbbVie, ArthritisPower; Y. Su, None; M. george, AbbVie/Abbott, GlaxoSmithKlein(GSK); C. Clinton, None; P. Stewart, None; T. Buekelman, UCB, Novartis; F. Xie, Bendcare.

To cite this abstract in AMA style:

Curtis J, Su Y, george M, Clinton C, Stewart P, Buekelman T, Xie F. Validation of New Medication User Definitions in Single-Specialty EHR Data [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/validation-of-new-medication-user-definitions-in-single-specialty-ehr-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-new-medication-user-definitions-in-single-specialty-ehr-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology